Skip to Content

Roche, Genentech Report Avastin Study Failure

From Associated Press (February 23, 2010)

NEW YORK -- Genentech said Tuesday the combination of its blockbuster cancer drug Avastin and Xeloda did not meet a late-stage study goal of extending the lives of advanced stomach cancer patients.

The company, a unit of Switzerland’s Roche, said it will present full results from the late-stage study at the 2010 American Society of Clinical Oncology’s annual meeting, taking place between June 4 and June 8.

Avastin is already approved to treat advanced colorectal, breast, lung and kidney cancer. Xeloda is approved as a breast and colectoral cancer treatment. The late-stage study specifically involved patients who either had inoperable or advanced stomach cancer. It compared the treatment regimen of Avastin, Xeloda and chemotherapy with patients only taking chemotherapy.

Posted: February 2010